Draft Notice Amending Designated Guidance-Required Drugs (PMD Act) - Public Comment
医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第四条第五項第三号の規定に基づき厚生労働大臣が指定する要指導医薬品の一部を改正する件（案）に関する御意見の募集について
Published: 2026-10-08 · Source: e-Gov Public Comment · Stage: Public Comment Open · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Medium · Comment deadline: 2026-11-07 00:00 JST · First detected by this dashboard: 2026-10-08
View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard
AI summary
Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.
Summary
The Ministry of Health, Labour and Welfare has opened a public comment solicitation on a draft notice partially amending the list of 'guidance-required drugs' (yōshidō iyakuhin) that the Minister designates under Article 4, paragraph 5, item 3 of the Pharmaceuticals and Medical Devices Act. The draft was published on 2026-10-08, and comments are accepted until 2026-11-07. The metadata does not specify which drugs would be added, removed, or changed.
Business Impact
If adopted, changes to the designated list could affect how certain drugs are classified and sold, which may be relevant to pharmaceutical manufacturers, importers, and pharmacies. The actual scope of any impact cannot be determined from the provided metadata.
Recommended Action
Review the official Japanese public comment page and the attached draft text to confirm the specific drugs affected and the submission procedure before the stated deadline.